Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib + Durvalumab in Metastatic Uveal Melanoma
NCT04184518Phase 2Withdrawn
- Start
- May 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib in Uveal melanoma (UM). Planned start May 2020; status: withdrawn.
02
Drugs
cediranib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT04184518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04184518.